The Pre-Approval Information Exchange Act of 2022, better known as the PIE Act, doesn’t seem very consequential at first glance. But returning guest Susan Weber thinks the PIE Act has the potential to be a real asset to pharma, market access and, ultimately, to patients.
Susan Weber is a Principal with Valuate Health. She recently authored a paper on the impact of the PIE Act, which you can read here.
Connect with Susan Weber on LinkedIn.
Follow Valuate on LinkedIn or visit us at ValuateHealth.com.